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Cardiovascular disease is a major cause of death in the Western World. Novel drugs and 
innovative devices have enhanced the quality of life for patients with cardiovascular 
disease, but such treatments are not without limitations and complications. The major 
constraint with these current treatments is the inability for growth, repair and remodeling of 
the structure. The emergence of tissue engineering as an alternative therapy for 
cardiovascular disease has generated an intensity of research into the development of many 
components of the cardiovascular system, including heart valves, small-calibre vascular 
grafts and biological stent materials. The composition of the biomaterial used as a support 
for the developing cardiovascular structure is a key mediator of cell behaviour and function 
in the tissue, and the ideal scaffold biomaterial for development of a successful end-product 
continues to be a matter of debate. Fibrin, a major structural protein involved in wound 
healing, represents an ideal scaffold for the rapid synthesis of autologous tissue-engineered 
cardiovascular grafts, as its primary scaffold constituents (fibrinogen and thrombin) can be 
isolated directly from a blood sample of the patient requiring the graft. Fibrin gel scaffolds 
offer immediate high cell seeding efficiency and homogenous cell distribution by gelation 
entrapment, and have a degradation rate that can be controlled by protease inhibitors, e.g. 
tranexamic acid or aprotinin. Fibrin is also known to stimulate the secretion of reinforcing 
extracellular matrix (ECM) proteins by seeded cells.  The potential to control the fibrin 
polymerisation process also offers the opportunity to produce complex 3-D structures, like 
heart valve prostheses and to embed porous, textile or metal (stent) structures. This book 
chapter reviews the properties of fibrin that make it an ideal scaffold candidate for 
applications in the area of cardiovascular tissue engineering, and documents the successful 
development of fibrin-based heart valves, vascular grafts and biostents for clinical application.  
2. Scaffold materials 
Scaffolds play a central role in cardiovascular tissue engineering. Essential requirements for 
the ideal cardiovascular scaffold are easy handling properties and the ability to mould 
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complex 3-D structures from the material, such as aortic roots or vessels with complex side 
branches. The scaffold material should neither be toxic, nor elicit any immunological side 
effects. The diffusion barrier of the scaffold material should have the lowest possible 
resistivity in order to guarantee an optimal nutrition supply in thicker tissues. Furthermore, 
both the mechanical and the chemical properties (e.g. the integration of growth factors) of 
the scaffold material should be modifiable. Controllable degradation of the material is also 
important in order to adapt the structural support of the scaffold with regard to the 
developing tissue.  
A multitude of scaffolds are currently employed in the field of tissue engineering, e.g. 
synthetic polymers (polyurethanes, polyglyolic acid, polylactic acid, polyhydroxybutyrate, 
copolymers of lactic and glycolic acids, polyanhydrides, polyorthoesters) and natural 
polymers (chitosan, glycosaminoglycans, collagen), or biological scaffolds such as 
acellularised porcine aortic conduits (Bader et al., 1998; Chevallay & Herbage, 2000; 
Flanagan et al., 2006; Freed et al., 1994; Grande et al., 1997). Scaffold-related problems 
including cytotoxic degradation products, fixed degradation times, limited mechanical 
properties and the absence of growth modulation, etc. necessitate further extensive 
investigations in developing the ideal cardiovascular scaffold.  
3. Fibrin as scaffold material? 
Based on the assumption that successful tissue engineering should mimic the process of 
tissue regeneration, and that regeneration is closely related to haemostatis, fibrin (gel) seems 
to be an ideal candidate as a tissue engineering scaffold by virtue of its role as a 
“physiological scaffold” in tissue regeneration. Several influences of fibrin gel on tissue 
development have been described in the literature: it is known that fibrin gel is one of the 
major ligands for ß3 integrins, which leads to cell migration into a wound/tissue-engineered 
construct (Ikari et al., 2000; Nomura et al., 1999). Thrombin, fibrinogen, fibrin monomers 
and fibrinopepide B all increase DNA synthesis in smooth muscle cells (SMCs) and 
consequently the proliferation of the cell (Pakala et al., 2001). 
3.1 Physiology of fibrin 
Fibrin is the end-product of the coagulation cascade following the conversion of fibrinogen 
in the presence of thrombin and calcium (Figure 1). Fibrinogen is a soluble plasma 
glycoprotein, which is produced by the liver. Fibrinogen is an acute phase protein with a 
normal blood concentration of 1.4 – 3.5 g/l. The fibrinogen molecule has a length of 45 nm, a 
molecular weight of 340 KDa and consists of 2 subunits and 3 polypeptides chains - α, β and 
γ. During the polymerisation process, the fibrinopeptide A of the α-chain and the 
fibrinopeptide B of the ß-chain are cleaved by thrombin. The exposed N-terminal positions 
of the fibrinopeptides bind to the γ-chain of the fibrinogen and produce the so-called 
proteofibrils. In the subsequent step, the lateral association leads to apposition of the 
proteofibrils to form a 3-D fibrin network structure (Meyer, 2004). FXIIIa stabilises fibrin 
further by incorporation of the fibrinolysis receptors, alpha-2-antiplasmin and TAFI 
(thrombin activatable fibrinolysis inhibitor, procarboxypeptidase B), and binding to several 
adhesive proteins of various cells (Muszbek et al., 2008). 
The polymerised fibrin gel matrix is a hydro-gel, which contains ~95-98% water. The water 
content can easily be exchanged against a buffer solution or a cell culture medium, allowing 
an optimal nutrition supply of the cells that are embedded after the gelation process. 
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Fig. 1. Coagulation cascade: the conversion of fibrinogen into fibrin is triggered by thrombin 
and calcium 
3.2 Production of autologous fibrin 
The classical approach for production of autologous fibrin is the cryoprecipitation method: 
after the production of platelet-poor plasma (PPP), the plasma is frozen at -80°C and thawed 
overnight at +4°C. The precipitate formed contains ~60-70% of fibrinogen. After 
centrifugation, the supernatant is decanted and the precipitate is subsequently washed twice 
in rinsed water. After the precipitate is dissolved in water, overnight dialysis against 
calcium-free TRIS buffer solution is necessary to provide optimal conditions for the 
embedded cells. 
The cryoprecipitation method has two major disadvantages: (1) the efficiency of fibrinogen 
isolation is relatively low with only ~20-25% of the total fibrinogen content removed, and (2) 
the production process is time-consuming (~2 days). The low isolation efficiency is 
particularly problematic regarding the use of autologous fibrin gel scaffolds in paediatric 
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patients, as the volume of sampled blood needs to be kept to an absolute minimum. 
Therefore, the use of alternative precipitation methods with different chemicals has been 
evaluated: (1) ethanol (Kjaergard et al., 1992; Weis-Fogh, 1988), (2) ammonium sulphate 
alone, and (3) in combination with the cryoprecipitation method (Wolf, 1983), (4) albumin 
plus cryoprecipitation, and (5) polyethylene glycol (PEG) plus cryoprecipitation (Epstein et 
al., 1986). Heselhaus investigated each of these different precipitation methods with regard 
to their efficiency and their use in the development of fibrin scaffold materials for 
cardiovascular applications (Heselhaus, 2011):  
 
 
Fig. 2. [A] Fibrin gel after polymerisation in a 6-well plate. [B-D] Scanning electron 
microscopy (SEM) images demonstrating the nano-fibre network structure of the fibrin, 
which enables the gentle embedding of cells, with a vascular smooth muscle cell (SMC) 
shown in [D] immediately after the gelation of the fibrin within a web-like network 
surrounded by cell culture medium 
Figure 3 demonstrates that all of the reported alternative methods are more efficient than 
the standard cryoprecipitation method. Here, the technique using ethanol as the 
precipitation reagent is observed as the most efficient method, with an isolation efficiency of 
~80%, ~4-times higher than the efficiency of the standard method. The technique applying 
both albumin and cryoprecipitation indicates a false positive high result due to 
contamination of the precipitate with albumin (shown by a significant band in SDS gel 
electrophoreses) (Heselhaus, 2011).  
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Fig. 3. Comparison of different precipitation methods for the isolation of fibrinogen (Cryo – 
cryoprecipitation; EtOH – ethanol; A.-S. – ammonium sulphate; Alb.–albumin;  
PEG – polyethylene glycol) 
3.3 Control of scaffold degradation (aprotinin vs. tranexamic acid) 
In nature, fibrin production and fibrinolysis are finely balanced. Figure 4 demonstrates the 
process of fibrinolysis induced by plasmin and the role of different regulatory factors, which 
stimulate and inhibit the fibrinolysis, respectively. 
In the context of in vitro cultivation, both of these processes are restricted by the limited 
concentration of substrates. This offers the opportunity to adapt the degradation of the 
fibrin scaffold material to the individual need during the tissue maturation process. Until 
recently, the most commonly used substrate to control the degradation of fibrin gel was 
aprotinin with a concentration of 130 K.I.U. per mL medium (Ye et al., 2000). Aprotinin is a 
polypeptide serine protease inhibitor, which stops fibrinolysis by inhibiting kallikrein, 
plasmin and platelet-activation factors. Aprotinin was used as anti-fibrinolyticum for many 
years in the clinic, but negative side-effects in the post-operative recovery phase of 
cardiothoracic patients led to the suspension of aprotinin in the worldwide market.  
Therefore, tranexamic acid (trans-4-aminomethely-cyclohexane-1-carboxylic acid; tAMCA) 
was evaluated as alternative drug to control fibrin gel degradation in vitro and as far as 
possible in vivo. Tranexamic acid is clinically approved and competitively inhibits the 
conversion of plasminogen into plasmin via reversibly binding to the lysine-binding site on 
plasminogen.  
Cholewinski et al. (2009) demonstrated that tranexamic acid at a concentration of 160 mg per 
mL medium has a comparable inhibition effect on fibrinolysis in comparison with aprotinin. 
Furthermore, no negative side-effects with regard to proliferation, apoptosis, necrosis or the 








Fig. 4. Balance between fibrin production and fibrinolyis ( →positive and --| negative effect) 
3.4 Fibrin as autologous growth factor delivery system (PDGF) 
The autologous source of fibrin, whole blood, contains a number of important growth 
factors. One major growth factor is the platelet-derived growth factor (PDGF), a cytokine 
produced in megacaryocytes and stored in the α-granules (Cianciolo et al., 1999; Ross et al., 
1986). PDGF has been described as one particular factor that positively influences 
proliferation, migration and ECM secretion of fibroblasts and SMCs (Claesson-Welsh, 1996). 
PDGF is released in conjunction with the platelet release reaction (Witte et al., 1978). Platelet 
activation induces the release of a variety of low-molecular weight growth factors and more 
than 60 of these growth factors are directly involved in tissue repair mechanisms such as 
chemotaxis, cell proliferation, angiogenesis, ECM deposition and remodelling (Borzini & 
Mazzucco, 2007). Platelets are easily isolated from blood, and can be concentrated in a low 
volume of plasma known as platelet-rich plasma (PRP). Thus, PRP is a storage vehicle for 
platelet growth factors. In addition to the abundant mixture of growth factors, PRP also 
contains proteins known to act as cell adhesion molecules and matrix for bone, connective 
tissue and epithelial migration, namely fibrin, fibronectin and vitronectin (Marx, 2004). 
PRP can be used as a fibrin-based scaffold material by inducing gel polymerisation. The use 
of PRP as an autologous scaffold material and growth factor delivery vehicle has attracted 
the attention of researchers in the field of tissue engineering as a new possibility to optimise 
the composition of the “ideal” autologous scaffold.  
To further optimise fibrin gel scaffolds, the use of PRP as a basis for autologous gel scaffolds 
instead of platelet-poor plasma (PPP) or pure fibrinogen solution has been evaluated. It was 
postulated that the use of PRP in contrast to PPP or fibrinogen solution as a basis for human 
autologous fibrin gels leads to an increased release of autologous PDGF-AB, which may 
have a consequent positive effect on tissue development. Therefore, a protocol for plasma 
preparation and subsequent plasma gel production was developed and the release kinetics 
of PDGF-AB from autologous plasma gels were investigated. Wirz and colleagues (2011) 
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analysed (i) the concentration of PDGF-AB in the PRP vs. PPP during gel preparation, (ii) 
the influence of plasma gels and particularly PDGF-AB (autologous and recombinant) on 
growth behaviour and cell proliferation, and (iii) the secretion of ECM by human umbilical 
cord artery smooth muscle cells (HUASMCs) in both plasma-based and pure fibrin gels. The 
study demonstrated that the use of PPP leads to almost complete loss of PDGF, whereas the 
use of PRP in combination with a concentration step (by a factor of two) retains almost 
serum levels of PDGF. The subsequent steps in the protocol allow the removal of all 
platelets without losing the PDGF in the concentrate (Wirz et al., 2011).  
But is the absence of platelets in the fibrin-based scaffolds good or not? To answer this 
question, Wirz et al. compared PDGF release from such fibrin-based scaffolds with and 
without incorporated platelets. Whereas the release of PDGF of platelet-rich and platelet-
free fibrin gels were similar during the first 3 days, the platelet-rich gels showed a 
significantly higher level of PDGF in the supernatant after the first medium exchange, 
indicating that the platelets with the α-granules continue to work as a ‘natural’ reservoir of 
the growth factor PDGF (Wirz et al., 2011). 
Nevertheless, against all expectations, the significantly higher level of PDGF-AB in fibrin 
gels was shown to have neither a significant influence on cell proliferation nor on the ECM 
synthesis of vascular SMCs. Although the vascular SMCs are the basic cell source for 
cardiovascular tissue engineering, these cells do not express the receptor for PDGF-A and 
lose the receptor for PDGF-B at a very early stage of in vitro primary cell culture (P0 to P4) 
(Wirz et al., 2011). Therefore, PDGF-rich fibrin gels may ultimately have a positive effect on 
fibroblasts and mesenchymal stem cells, for example, but not on primary vascular SMCs. 
 
 
Fig. 5. PDGF-AB release of platelet poor plasma (PPP), platelet rich plasma (PRP) before and 
after cryoprecipitation, after concentration of the plasma volume (by a factor of two), and 
after sterile filtration process (0.22µm filter) 
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4. Examples of fibrin-based cardiovascular tissue engineering 
4.1 Heart valve 
The principles of fibrin-based cardiovascular tissue engineering can be demonstrated using 
the example of a completely autologous heart valve prosthesis as shown in Figure 6 
(Jockenhoevel et al., 2001b). For paediatric application, the umbilical cord is the optimal cell 
source. The umbilical cord contains the myofibroblasts/vascular SMCs, which are 
responsible for the structural and mechanical stability of the neo-tissue. Furthermore, the 
endothelial cells of the umbilical cord vein are an ideal cell source for the luminal coating of 
cardiovascular structures. The endothelial cells are mainly responsible for the 
haemocompatibility of the tissue-engineered graft. The third component of the umbilical 
cord that is applicable to tissue engineering is the blood, from which the compounds for 
autologous fibrin-gel synthesis can be extracted. 
 
 
Fig. 6. Principles of fibrin-based tissue engineering using the example of a completely 
autologous heart valve prosthesis 
Based on clinical imaging methods such as echocardiography, it is possible to manufacture a 
mould that is customised for the individual. This allows the surgical correction of complex 
congenital heart defects with a shape-optimised implant.  
The production of the basic heart valve structure is realised using an injection moulding 
technique: at the outset, the first of two essential components is produced, and consists of 
myofibroblasts suspended in a buffer solution that is supplemented with calcium and 
thrombin. The second component consists of the autologous fibrinogen solution. With a 2-
piston-dual syringe system, both components are injected into the customised mould, which 
consists of a negative and positive stamp. The gelation process begins immediately and 
homogenously entraps the myofibroblasts in the fibrin gel. After the gel polymerisation is 
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complete, the newly moulded heart valve conduit is decast from the mould and transferred 
into a bioreactor system. A suitable nutrition supply and biomechanical stimulation are 
essential for the maturation of these tissue-engineered structures, as they are too fragile at 
the outset for direct implantation (Flanagan et al., 2007).  
After preconditioning in the bioreactor system, the mechanically stable heart valve 
prosthesis has been developed. The lining of the luminal surface with autologous 
endothelial cells is the final production step and is important for complete immunological 
integrity and physiological haemostasis. At the end of the production chain, a completely 
autologous heart valve implant is realised, which has the ability to withstand the mechanical 
properties in the low pressure/pulmonary circulation, as demonstrated previously 
(Flanagan et al., 2009). 
4.2 Vascular graft 
Autologous vascular grafts based on a fibrin scaffold have also been developed for 
applications in a number of settings, including coronary artery and peripheral artery bypass 
procedures, arteriovenous access grafts for haemodialysis patients, or in the paediatric 
setting for congenital pulmonary artery reconstruction. Fibrin alone does not possess 
sufficient mechanical properties for direct implantation into the high pressure setting of 
small-calibre arteries (< 6 mm); therefore, the fibrin-based grafts are supported by a 
bioabsorbable, macroporous mesh (poly(L/D)lactide 96/4; PLA) with a controlled 
degradation profile, which acts as a temporary supporting system upon implantation until 




Fig. 7. Bioresorbable, macroporous mesh with a pore size of ~ 1mm before [A] and after [B] 
the embedding into the fibrin/cell matrix. [C] Fibrin-based vascular graft after implantation 
in the arterial circulation (ovine carotid model) 
The synthesis of the fibrin-based vascular graft is based on similar principles to those used 
in developing the autologous fibrin-based heart valve (i.e. injection moulding technique). 
Once the vascular grafts are constructed in a tubular mould, however, the mould acts as the 
bioreactor system and is connected to a flow support that imparts pulsatile luminal flow to 
the graft. We have shown for the first time that fibrin-based vascular grafts attain a 
supraphysiological burst strength sufficient for arterial implantation after just 21 days of 
mechanical conditioning in such a bioreactor system (Tschoeke et al., 2008). We followed up 
this report with a preclinical study in a large animal model, which presented data on the 
first series of fibrin-based grafts to be implanted in the arterial circulation (ovine carotid 
model) (Koch et al., 2010). In this model, the grafts showed no evidence for thrombus 
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formation, aneurysm, calcification or infection, and remained patent for at least 6 months in 
vivo. The grafts maintained a functional endothelial lining in vivo, and the fibrin-based 
scaffold was completely replaced by autologous connective tissue elements (e.g. collagen, 
elastin) after 6 months of implantation (Koch et al., 2010).  
4.3 BioStent 
During recent years, percutaneous stent angioplasty has become well established in the 
treatment of peripheral and coronary atherosclerosis. Nevertheless, the patency rates in 
small-calibre vessels, particularly those of the femoral and femoropopliteal region, are not 
satisfactory (Cejna et al., 2001; Grenacher et al., 2004; Schillinger et al., 2006).The incessant 
problem of instent restenosis is a result of: (1) the proliferation stimulus resulting from the 
pressure trauma of stent implantation (>10 bar in non-self-expanding stents), which leads to 
(2) an ingrowth of myofibroblasts through the gap of the stent structure, and (3) an 
increased production of ECM proteins; (4) finally, acute thrombotic occlusion can occur in 
the stented segment of the vessel. Occlusion rates of more than 20% after 6 months could be 
overcome with a viable stent prosthesis that includes a confluent, functionally active 
endothelial cell layer from the outset. 
 
 
Fig. 8. Concept of the BioStent [A]: the knitted, self-expanding Nitinol-Stent [B] is embedded 
into a fibrin-cell matrix [C] and can be deployed without tissue destruction [D]. H&E 
staining demonstrates a complete coating of the Nitinol stent structure with viable tissue [E] 
The BioStent concept merges the principles of self-expanding stent technology with those of 
vascular tissue engineering: the moulding process of vascular grafts based on a fibrin gel 
scaffold allows the complete integration of a self-expanding stent structure within the tissue-
engineered vessel. This process leads to a complete exclusion of the atherosclerotic section of 
the vessel from the blood stream on the one hand, and coating of the neo-lumen with a 
functional endothelial cell layer on the other hand (Figure 8).   
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The BioStent concept is a platform technology, i.e. by applying different cell types, a number 
of alternative therapies can be addressed, including (1) endobronchial stenting using 
respiratory epithelium, (2) oesophageal stenting using mucosa cells, or (3) urological 
stenting using urothelial cells, etc.  
5. Summary 
In our opinion, fibrin gel combines a number of important properties of an ideal scaffold for 
cardiovascular tissue engineering:  
• Fibrin gel is a naturally-occurring scaffold that can be isolated as an autologous 
substrate from blood of the patient in question (Heselhaus, 2011); 
• Starting with a cell suspension in fibrinogen solution, fibrin gel scaffolds offer 
immediate high cell seeding efficiency and homogenous cell distribution by gelation 
entrapment, with a minimal loss of cells during the seeding procedure; furthermore, 
there is no time-consuming cell ingrowth from the scaffold surface to the deeper parts 
of the scaffold (Jockenhoevel et al., 2001a);  
• Polymerisation as well as degradation of the fibrin gel is controllable and can be 
adapted to tissue development through the use of the protease inhibitors, such as  
aprotinin and tranexamic acid (Cholewinski et al., 2009); 
• Local, covalent immobilisation of different growth factors is possible, while PRP gels 
can be developed to enhance the content and delivery of growth factors (Wirz et al., 
2011); 
• Production of complex 3-D structures such as heart valve conduits or vascular grafts 
with complex side branches is possible through the use of an injection moulding 
technique (Flanagan et al., 2007; Jockenhoevel et al., 2001b); 
• Textile-reinforced fibrin-based grafts can be implanted in the arterial circulation and 
function for at least 6 months in vivo (Koch et al., 2010); 
• Fibrin-based tissue engineering can be merged with self-expanding stents to create a 
platform technology for cardiovascular, and other, diseases. 
These properties highlight the significant potential for creation of functional, autologous 
implantable cardiovascular prostheses in future using tissues derived from the patient. 
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